| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0001525 | Angiogenesis | Decreases phenotype | PMID:36206955 |
| GO:0001787 | Natural killer cell proliferation | Decreases phenotype | PMID:30171972 |
| GO:0001836 | Release of cytochrome c from mitochondria | Increases phenotype | PMID:26878773 |
| GO:0002503 | Peptide antigen assembly with mhc class ii protein complex | Increases phenotype | PMID:30021835 |
| GO:0002539 | Prostaglandin production involved in inflammatory response | Increases phenotype | PMID:23942037 |
| GO:0004602 | Glutathione peroxidase activity | Decreases phenotype | PMID:32565124 |
| GO:0004784 | Superoxide dismutase activity | Affects phenotype | PMID:26878773; PMID:32565124; PMID:37075934; PMID:37393915 |
| GO:0006749 | Glutathione metabolic process | Increases phenotype | PMID:27774770; PMID:29857117; PMID:30244016; PMID:30547568; PMID:32565124; PMID:37716422 |
| GO:0006750 | Glutathione biosynthetic process | Affects phenotype | PMID:24970285; PMID:25305463; PMID:27178040 |
| GO:0006915 | Apoptotic process | Increases phenotype | PMID:26878773; PMID:28583816; PMID:32428544; PMID:37075934 |
| GO:0006954 | Inflammatory response | Increases phenotype | PMID:32565124 |
| GO:0006974 | Cellular response to dna damage stimulus | Increases phenotype | PMID:28583816 |
| GO:0007005 | Mitochondrion organization | Decreases phenotype | PMID:31726083 |
| GO:0007283 | Spermatogenesis | Affects phenotype | PMID:32565124 |
| GO:0007605 | Sensory perception of sound | Affects phenotype | PMID:32428544 |
| GO:0008219 | Cell death | Increases phenotype | PMID:32428544 |
| GO:0008283 | Cell population proliferation | Decreases phenotype | PMID:24970285; PMID:32565124 |
| GO:0008285 | Negative regulation of cell population proliferation | Increases phenotype | PMID:29966676; PMID:30547568 |
| GO:0009410 | Response to xenobiotic stimulus | Affects phenotype | PMID:33148531 |
| GO:0010460 | Positive regulation of heart rate | Increases phenotype | PMID:28844481 |
| GO:0010701 | Positive regulation of norepinephrine secretion | Increases phenotype | PMID:28844481 |
| GO:0010917 | Negative regulation of mitochondrial membrane potential | Increases phenotype | PMID:31423616; PMID:37393915 |
| GO:0010940 | Positive regulation of necrotic cell death | Increases phenotype | PMID:35724838 |
| GO:0010942 | Positive regulation of cell death | Increases phenotype | PMID:22466069; PMID:23942037; PMID:26879219 |
| GO:0014068 | Positive regulation of phosphatidylinositol 3-kinase signaling | Affects phenotype | PMID:23829535 |
| GO:0016042 | Lipid catabolic process | Increases phenotype | PMID:24970285; PMID:26878773; PMID:28583816; PMID:32565124 |
| GO:0030101 | Natural killer cell activation | Increases phenotype | PMID:30171972; PMID:32702509 |
| GO:0030316 | Osteoclast differentiation | Increases phenotype | PMID:23112101 |
| GO:0032689 | Negative regulation of type ii interferon production | Affects phenotype | PMID:22250088 |
| GO:0032736 | Positive regulation of interleukin-13 production | Affects phenotype | PMID:22250088 |
| GO:0032753 | Positive regulation of interleukin-4 production | Affects phenotype | PMID:22250088 |
| GO:0032754 | Positive regulation of interleukin-5 production | Affects phenotype | PMID:22250088 |
| GO:0033212 | Iron import into cell | Increases phenotype | PMID:37393915 |
| GO:0034440 | Lipid oxidation | Increases phenotype | PMID:27774770; PMID:37716422 |
| GO:0035148 | Tube formation | Decreases phenotype | PMID:36206955 |
| GO:0036091 | Positive regulation of transcription from rna polymerase ii promoter in response to oxidative stress | Increases phenotype | PMID:27473261; PMID:33838154 |
| GO:0042167 | Heme catabolic process | Increases phenotype | PMID:23942037 |
| GO:0042743 | Hydrogen peroxide metabolic process | Affects phenotype | PMID:32565124 |
| GO:0043065 | Positive regulation of apoptotic process | Increases phenotype | PMID:25341683; PMID:25645596; PMID:29857117; PMID:31423616; PMID:35724838 |
| GO:0043388 | Positive regulation of dna binding | Affects phenotype | PMID:22250088 |
| GO:0043392 | Negative regulation of dna binding | Affects phenotype | PMID:22250088 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:31311324; PMID:31726083; PMID:32334435; PMID:32428544; PMID:37075934; PMID:37716422 |
| GO:0044319 | Wound healing, spreading of cells | Decreases phenotype | PMID:36206955 |
| GO:0045429 | Positive regulation of nitric oxide biosynthetic process | Increases phenotype | PMID:23942037 |
| GO:0045453 | Bone resorption | Increases phenotype | PMID:23112101 |
| GO:0045454 | Cell redox homeostasis | Affects phenotype | PMID:37393915 |
| GO:0045581 | Negative regulation of t cell differentiation | Affects phenotype | PMID:22250088 |
| GO:0045582 | Positive regulation of t cell differentiation | Affects phenotype | PMID:22250088 |
| GO:0045930 | Negative regulation of mitotic cell cycle | Increases phenotype | PMID:26878773 |
| GO:0048469 | Cell maturation | Increases phenotype | PMID:30171972 |
| GO:0050996 | Positive regulation of lipid catabolic process | Increases phenotype | PMID:37393915 |
| GO:0051092 | Positive regulation of nf-kappab transcription factor activity | Increases phenotype | PMID:28844481 |
| GO:0051881 | Regulation of mitochondrial membrane potential | Affects phenotype | PMID:26878773; PMID:37716422 |
| GO:0051899 | Membrane depolarization | Increases phenotype | PMID:37075934 |
| GO:0060326 | Cell chemotaxis | Decreases phenotype | PMID:36206955 |
| GO:0061370 | Testosterone biosynthetic process | Affects phenotype | PMID:32565124 |
| GO:0070994 | Detection of oxidative stress | Increases phenotype | PMID:37075934 |
| GO:0072593 | Reactive oxygen species metabolic process | Increases phenotype | PMID:31423616; PMID:32428544; PMID:36343453; PMID:36786954; PMID:37716422 |
| GO:0090200 | Positive regulation of release of cytochrome c from mitochondria | Increases phenotype | PMID:31423616 |
| GO:0097722 | Sperm motility | Decreases phenotype | PMID:32565124 |
| GO:0098683 | Cochlear hair cell ribbon synapse | Decreases phenotype | PMID:32428544 |
| GO:0140042 | Lipid droplet formation | Increases phenotype | PMID:24484068 |
| GO:1900181 | Negative regulation of protein localization to nucleus | Increases phenotype | PMID:33148531; PMID:35122929 |
| GO:1900182 | Positive regulation of protein localization to nucleus | Increases phenotype | PMID:29788535; PMID:30965670; PMID:33148531; PMID:35724838 |
| GO:1900409 | Positive regulation of cellular response to oxidative stress | Increases phenotype | PMID:37393915 |
| GO:1901098 | Positive regulation of autophagosome maturation | Decreases phenotype | PMID:23589329 |
| GO:1901671 | Positive regulation of superoxide dismutase activity | Decreases phenotype | PMID:27774770 |
| GO:1903409 | Reactive oxygen species biosynthetic process | Increases phenotype | PMID:24970285; PMID:26878773; PMID:28583816; PMID:30476502; PMID:31726083 |
| GO:1903428 | Positive regulation of reactive oxygen species biosynthetic process | Increases phenotype | PMID:27774770; PMID:28844481; PMID:29857117; PMID:35122929; PMID:37393915 |
| GO:2000481 | Positive regulation of camp-dependent protein kinase activity | Affects phenotype | PMID:23829535 |
| GO:2000553 | Positive regulation of t-helper 2 cell cytokine production | Affects phenotype | PMID:22250088 |
| GO:2000786 | Positive regulation of autophagosome assembly | Increases phenotype | PMID:23589329 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.